There is a newer version of the record available.

Published June 5, 2019 | Version v5
Dataset Open

Industry-scale Application and Evaluation of Deep Learning for Drug Target Prediction

  • 1. Clinical Pharmacology and Safety Science, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden
  • 2. LIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz, Altenbergerstr 69, 4040 Linz, Austria
  • 3. Computational Biology, Discovery Sciences, Janssen Pharmaceutical, Turnhoutseweg 30, 2349, Beerse, Belgium
  • 4. Computational Biology, Discovery Sciences, Janssen Pharmaceutica NV, 1400 McKean Rd, 19002, Spring House, Pennsylvania US
  • 5. Computational Biology, Discovery Sciences, Janssen Cilag SA, Calle Río Jarama, 71A, 45007, Toledo, Spain
  • 6. Ideaconsult Ltd., 4. Angel Kanchev Str., 1000 Sofia, Bulgaria
  • 7. Intel Corporation, Data Center Group, Veldkant 31, 2550 Kontich, Belgium.
  • 8. IT4Innovations, VSB – Technical University of Ostrava, 17. Listopadu 15/2172, 70800, Ostrava-Poruba, Czech Republic
  • 9. Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden

Description

Artificial intelligence (AI) is undergoing a revolution thanks to the breakthroughs of machine learning algorithms in computer vision, speech recognition, natural language processing and generative modelling. Recent works on publicly available pharmaceutical data showed that AI methods are highly promising for Drug Target prediction. However, the quality of public data might be different than that of industry data due to different labs reporting measurements, different measurement techniques, fewer samples and less diverse and specialized assays. As part of a European funded project (ExCAPE), that brought together expertise from pharmaceutical industry, machine learning, and high-performance computing, we investigated how well machine learning models obtained from public data can be transferred to internal pharmaceutical industry data. Our results show that machine learning models trained on public data can indeed maintain their predictive power to a large degree when applied to industry data. Moreover, we observed that deep learning derived machine learning models outperformed comparable models, which were trained by other machine learning algorithms, when applied to internal pharmaceutical company datasets. To our knowledge, this is the first large-scale study evaluating the potential of machine learning and especially deep learning directly at the level of industry-scale settings and moreover investigating the transferability of publicly learned target prediction models towards industrial bioactivity prediction pipelines.

Files

Files (2.1 GB)

Name Size Download all
md5:1f438d5dff7edf84593e0b880da84c13
2.1 GB Download

Additional details

Funding

ExCAPE – Exascale Compound Activity Prediction Engine 671555
European Commission